for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-AstraZeneca Says Fasenra Eliminated Oral Corticosteroid Use In A Majority Of OCS-Dependent Patients With Asthma In Ponente Phase IIIb Trial

Oct 29 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA - FASENRA ELIMINATED ORAL CORTICOSTEROID USE IN A MAJORITY OF OCS-DEPENDENT PATIENTS WITH ASTHMA IN PONENTE PHASE IIIB TRIAL Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up